CEBPG抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Hela and RAW264.7 cell lysates, Primary antibody: P07191(CEBPG Antibody) at dilution 1/550, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 7 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P07191(CEBPG Antibody) at dilution 1/80. (Original magnification: ×200)    

  
  

The CEBPG antibody is designed to detect the CCAAT/Enhancer-Binding Protein Gamma (CEBPG), a member of the CEBP transcription factor family. CEBPG plays a regulatory role in cellular processes such as proliferation, differentiation, inflammation, and metabolism by binding to DNA as a homodimer or heterodimer with other CEBP family members (e.g., CEBPα, β). It is involved in cytokine signaling, immune responses, and stress pathways, with studies linking it to cancer progression, metabolic disorders, and immune diseases.

CEBPG antibodies are widely used in research to study its expression, localization, and function via techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and chromatin immunoprecipitation (ChIP). These antibodies are typically raised in hosts such as rabbits or mice, available as monoclonal or polyclonal forms, and validated for specificity against recombinant or endogenous CEBPG.

Research applications include exploring its role in tumorigenesis (e.g., regulating apoptosis in leukemia), metabolic regulation (e.g., lipid metabolism), and inflammatory diseases. Commercial antibodies often cite peer-reviewed validation data, ensuring reliability for experimental reproducibility. Proper controls (e.g., knockout cell lines) are recommended to confirm antibody specificity. Understanding CEBPG's mechanisms through such tools contributes to therapeutic targeting in diseases where its dysregulation is implicated.